Multiple Sclerosis Centers of Excellence
Dimethyl Fumarate (Tecfidera, Generic)
Dimethyl fumarate (Tecfidera) is an oral medication, taken every 12 hours, for the treatment of relapsing forms of MS. Dimethyl fumarate and its metabolites have been shown to activate the nuclear factor (erythroid-derived 2)-like 2 (Nrf2) pathway in vitro and in vivo in animals and humans. The Nrf2 pathway is involved in the cellular response to oxidative stress. Monomethyl fumarate has been identified as a nicotinic acid receptor agonist in vitro. Dimethyl Fumarate Delayed-Release Capsules is an FDA-approved therapeutic equivalent to Tecfidera.
Additional Information
Disclaimer: Links are provided as a convenience and for informational purposes only. They do not constitute an endorsement or an approval by MSCoE of any of the products, services, or opinions of the organization. MSCoE bears no responsibility for the accuracy, legality, or content of the external site or for that of subsequent links. Contact the external site for answers to questions regarding its content.